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ABSTRACT 
The retina offers a unique window to the brain with its unmyelinated axons that converge to the 
optic nerve. Optical coherence tomography (OCT) is a well-established and non-invasive imaging 
technique in the ophthalmology field. The retinal layers can be imaged directly, and OCT is often 
described as an optical biopsy of retinal tissue. OCT has many practical advantages, as ease of use, 
short acquisition time and being relatively inexpensive. During the past decade the interest in OCT 
has grown in the neurology field and its potentials as an imaging modality that might complement 
magnetic resonance imaging (MRI). Multiple sclerosis is a complex chronic neurological disease 
that leads to both gray and white matter damage. OCT has shown promising results in several 
studies focusing on MS and neurodegeneration in the brain. 
Paper 1 evaluated the repeatability of images taken by Canon OCT-HS100 with the new automatic 
eye track function. The results showed good correlation with the well-established Zeiss Cirrus HD-
OCT 5000, however it was clear that OCTs are not interchangeable due to differences in thickness 
estimations. Paper 2 confirmed in a large MS cohort, findings from previous studies that the 
peripapillary retinal nerve fiber layer (pRNFL) is reduced in eyes of MS patients compared with 
healthy controls (HCs), regardless of optic neuritis (ON) history. The temporal quadrant of pRNFL 
(T-pRNFL) demonstrated the strongest correlation to both physical disability, assessed with the 
Expanded Disability Status Scale (EDSS) and cognitive impairment, measured with Symbol Digit 
Modalities Test (SDMT). Paper 3 aimed to evaluate different OCT parameters in MS patients and 
investigate which might best describe physical disability and cognitive impairment. All of four 
included OCT measures showed a statistically significant thickness reduction in MS eyes compared 
with HCs. The T-pRNFL of primary progressive MS patients had the largest atrophy of the inner 
retinal layers compared with HCs. The EDSS showed a strong and significant inverse correlation 
with all four OCT measures. SDMT had the strongest correlation with average pRNFL and T-
pRNFL thicknesses. 
In conclusion, OCT is a sensitive method to assess structural damage of neurons and their axons in 
the visual pathway in MS. It is a reliable imaging technique with high repeatability. Retinal 
thickness loss was found in all MS subtypes and is associated with both physical and cognitive 
dysfunction. Our findings suggest the usefulness of measuring pRNFL thickness with OCT in MS 
eyes. In particular, the T-pRNFL thickness might be an important measurement to differentiate MS 
subtypes. 
Keywords: Optical coherence tomography, Multiple sclerosis, Peripapillary retinal nerve fiber 
layer, Ganglion cell – inner plexiform layer, Physical disability, Cognitive impairment 
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1 PREFACE 
During my master’s studies I worked on a project about evaluating a certain electrode’s 
capability to directly measure electrical activity of the ciliary muscle during accommodation. 
The aim was also to investigate if accommodation triggers electrical activity in several 
muscles of the neck and upper back and if this would correlate with the ciliary muscle 
activity. While working on the project I found myself very interested in research. After the 
master’s program I got the opportunity to apply for a doctoral project. The main purpose of 
the project was initially to evaluate different techniques for the measurements of structure and 
function of the eye. My supervisor had an idea to evaluate ocular structure and function in 
patients with multiple sclerosis (MS) and during a division visit by the head of department 
this idea was again brought up. The head of department immediately got interested and 
promised to engage himself in this idea being realized. So more or less unexpectedly, our 
research group changed its focus and became involved in MS research focusing on optical 
coherence tomography (OCT). OCT in MS had only been done sparsely in Sweden and 
international studies showed positive results of using OCT in MS. So, from that day my 
project took another direction, i.e., towards structural retinal measurements.  
 8 
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2 INTRODUCTION 
Medical imaging technologies have advanced dramatically over the last decade. Imaging is 
now essential to improve diagnosis accuracy and to create a good foundation to aid 
therapeutic decisions and future follow ups. New techniques do not only need to be compared 
with already established instruments, the repeatability must also be evaluated. Today the 
magnetic resonance imaging (MRI) is the most important tool for neurological conditions. 
MRI is a non-invasive technique; however it is also time consuming, expensive and 
uncomfortable for the patient (1). The ideal methods for monitoring axonal damage will be 
specific, inexpensive and can be performed quickly and frequently. These ideal methods 
should also monitor disease progression and response to therapy. 
In many diseases, such as MS, an early diagnosis and the possibility for accurate quantitative 
measures of disease progress are crucial for clinical decision making and the patient’s well-
being. The retina is a unique central nervous system (CNS) structure with its unmyelinated 
ganglion cell axons, making it possible to image the axons directly. The back of the eye can 
be considered as the front of the brain, and already in 1974 Frisén et al. observed defects of 
the peripapillary retinal nerve fiber layer (pRNFL) in MS patients using ophthalmoscopy (2). 
By quantifying the RNFL and macular thickness, it might be possible to monitor axonal and 
neuronal damage (3). It is also important to investigate if structural changes correlate with 
disability. The afferent visual pathway is easy to investigate both structurally and 
functionally. Retinal tissue imaging is easily performed using OCT. This non-invasive 
technique has revolutionized the ophthalmology field and is nowadays a very important 
imaging tool when diagnosing several eye conditions. 
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2.1 AIMS OF THE THESIS 
This thesis consists of three studies and the purpose was to investigate the potentials of OCT 
to assess retinal degeneration in patients with MS. The specific aim of each study was: 
Paper 1: To investigate the repeatability of optic disc and macular measurements in healthy 
eyes obtained from Canon OCT-HS100 when using automatic tracing. 
Paper 2: To assess the potential of measuring pRNFL thickness with OCT in MS eyes, both 
with and without optic neuritis history, and correlate it with commonly used functional tests 
in the MS field. 
Paper 3: To compare different OCT parameters between MS patients and healthy controls 
and to investigate these parameters as predictive values for future physical disability and 
cognitive impairment in MS. 
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3 BACKGROUND 
The first part of the background section of this thesis provides some basic concepts regarding 
the structure and function of the retina and visual pathway. Next, this background chapter 
focuses on the history and technology of OCT and how it has evolved since it was introduced 
a quarter of a decade ago. Thereafter, a section about MS with its impact on vision and close 
relationship to optic neuritis (ON) will follow. The last part of this chapter will give the 
reader the basic concepts about commonly used assessment scales in clinical practice and 
treatment trials for MS. 
3.1 THE RETINA 
The retina lines the back of the eye with a total diameter of 30-40 mm (4) and is composed of 
several different layers (Figure 1). Even though the retina contains many millions of neurons, 
there are only five different types of neurons in the retina.  
The retinal pigment epithelium (RPE) is a single sheet of polygonal, melanin-containing cells 
situated on the Bruch’s membrane. The photoreceptors are in connection with the RPE layer 
and consists of an inner and an outer segment (IS/OS). The external limiting membrane 
(ELM) has intercellular junctions and divides the inner segment of the photoreceptor from its 
cell body and synaptic terminal. The outer nuclear layer (ONL) contains the cell bodies of the 
photoreceptors. The outer plexiform layer (OPL) is the first synaptic zone and consists of 
synapses connecting the photoreceptors to the horizontal cells and the bipolar cells. The inner 
nuclear layer (INL) contains the cell bodies of horizontal cells, bipolar cells, amacrine cells 
and Müller cells. The bipolar cells terminate on the amacrine cells and ganglion cells in the 
inner plexiform layer (IPL), which is the second synaptic zone of the retina. The ganglion cell 
layer (GCL) contains the cell bodies of the ganglion cells. The RNFL is composed of the 
ganglion cell axons which form the optic nerve. The inner limiting membrane (ILM) is the 
basement membrane of the Müller cells and represents the border between the retina and the 
vitreous body (5). 
Vision is initiated by phototransduction, a process when light is converted into an electrical 
signal by the photoreceptors. The photoreceptors outer segment contains the light sensitive 
visual pigment rhodopsin. When light is absorbed by rhodopsin a receptor potential will 
trigger a chain of events that amplifies the electrical signal to the rest of the photoreceptor (6, 
7).  
The visual information arising in the photoreceptors travel through the bipolar cells to the 
ganglion cells. The photoreceptors consist of rods and cones. The rods have very low spatial 
resolution but are extremely sensitive to light and are responsible to low-light vision. Cones, 
on the other hand, have high resolution, but are insensitive to light and mediate daylight 
vision and color vision (8). The bipolar cells connect the outer and the inner retina and these 
cells contact every other retinal neuron type (9). They receive electrical impulses directly 
from the photoreceptors or indirectly from the horizontal cells and carries the information to 
the IPL where they synapse on ganglion cells. More than ten types of bipolar cells are present 
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in the retina. The horizontal cells are spread horizontally in the INL and regulate the input 
from photoreceptors to bipolar cells (10, 11). Amacrine cells have the highest variety of all 
cells in the retina and 30 different types have been identified. They have an inhibitory nature 
and stand in connection with bipolar and/or ganglion cells (12).  
 
Figure 1. Illustration by L. Pettersson of the retinal layers. The illustration is printed with 
permission from the illustrator and is modified from Hansen (13). 
3.2 VISUAL PATHWAY 
The ganglion cell axons exit the retina through the optic disc and form the optic nerve. The 
optic nerve axons travel to the optic chiasm where most axons will undergo a partial 
decussation and afterwards enter one of the two optic tracts. The optic tracts consist of axons 
from both eyes and most of them will terminate in the lateral geniculate nucleus, the thalamic 
relay nucleus for vision (5). The lateral geniculate nucleus both separates the input from each 
eye into different layers and from different types of ganglion cells. The main types of 
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ganglion cells are the parvocellular neurons (midget cells) and the magnocellular neurons 
(parasol cells). The small parvocellular neurons, mostly found in the fovea, detects fine 
details and are responsible for the “what”-pathway, are sensitive to color and form (5, 8). The 
magnocellular ganglion cells, which are predominant in the peripheral retina, have larger cell 
bodies and axons than the parvocellular neurons and are concerned with the “where”-
pathway. They are “color blind”, detects motion and have high-contrast sensitivity (8, 14). 
The internal capsule contains many projecting fibers and is divided in five different regions. 
The retrolenticular region of the internal capsule contains the optic radiation. The axons of 
the optic radiation, originating in the lateral geniculate nucleus, consist of three fiber bundles 
and they terminate in the calcarine sulcus of the occipital cortex (8). The axons of the optic 
radiation give rise to a retinotopic map. The ventral/anterior bundle, called the Meyer’s loop, 
are the axons representing the inferior retinal quadrants, that give rise to the superior visual 
field quadrants. These axons loop deeply into the anterior temporal lobe before taking a turn 
backwards to the anteroinferior portion of the calcarine sulcus (15, 16). The central bundle 
occupies a large middle area of the optic radiation fibers and corresponds to the macular 
region, i.e. the central visual field (5). The dorsal/posterior bundle, the Baum’s loop, are the 
axons representing the superior retinal quadrants, that give rise to the inferior visual field 
quadrants. These axons projects superiorly towards the occipital cortex through the parietal 
lobe (17). An overview of the visual pathway is illustrated in Figure 2. 
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Figure 2. Illustration of the visual pathway from the retina to the primary visual cortex by L. 
Pettersson. The illustration is printed with permission from the illustrator and is modified 
from Hansen (13). 
3.3 OPTICAL COHERENCE TOMOGRAPHY 
3.3.1 History 
Optical coherence tomography (OCT) was first described in 1991 by Huang et al. as a non-
invasive imaging technique for evaluation of biological systems in vitro (18). Two years later 
the technique was presented as an in vivo imaging of healthy human retinas (19, 20). A few 
years later imaging of several macular diseases was performed for the first time with OCT 
(21). The technique has since then become an accepted and powerful diagnostic tool for 
retinal pathologies and reveals a potential decrease in RNFL and macular thickness (22, 23). 
Today it is used for evaluation and follow-up of several retinal conditions and diseases, such 
as macular holes (24), epiretinal membranes (25), macular edema (26) and glaucoma (27). 
The images obtained are very similar to histologic sections and the technique might be 
considered as in vivo histology (23). 
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3.3.2 Basic principles of the technique 
The principle technique of OCT uses light waves to take cross-sectional images of retinal 
tissue structure in real time. It is based on an echo technique and the principle is almost the 
same as ultrasound imaging, but instead of using sound, it uses light. The OCT images have 
higher resolution compared with ultrasound or radiofrequency. It uses a low-coherent, super 
luminescent diode of near-infrared light (approximately 840 nm), which is divided by a 
beam-splitter into a reference beam and a detection beam (18). The reference beam goes to a 
reference mirror and the detection beam goes to the eye. The reference beam is then reflected 
by its mirror and the detection beam is backscattered with different time delays by the retinal 
tissue. The beams are then recombined through the beam splitter, detected by a photo detector 
and an image is obtained by comparing the time difference in the backscattered light from the 
different retinal layers with the light reference reflection. The intensity of backscattered light 
at different retinal depths at a single location will provide structural information, known as A-
scans. Combining multiple A-scans gives two-dimensional images, called B-scans.  
Time-domain OCT (TD-OCT), the old generation of OCT, uses a moving reference mirror 
which gives a very slow scanning speed. The commercially available TD-OCT Stratus OCT 
(Carl Zeiss Meditec, Dublin, CA) produces 400 A-scans per second with an axial resolution 
of 8-10 µm. However, the newer technique, spectral-domain OCT (SD-OCT), uses a fixed 
reference mirror and the photo detector is replaced by a spectrometer (28). This makes the 
scanning speed much faster with at least 25,000 A-scans per second and three-dimensional 
images are obtained (29). The axial resolution is 3-6 µm. In comparison with TD-OCT, it is 
possible to quantify the different retinal layers individually with the technology of SD-OCT. 
In 2012, Canon launched the SD-OCT HS100 (Figure 3). The scan speed is 70,000 A-scans 
per second, which enables a short examination time. The axial resolution is 3 µm. The 
scanning width varies between 2 and 10 mm, depending on type of scan. The Canon OCT-
HS100 is further described in the Methods section. 
The latest generation of OCT, swept source OCT (SS-OCT), has recently been introduced. In 
SS-OCT, the super luminescent diode is replaced by a tunable, short cavity swept laser and a 
spectrometer is not used (30). The laser changes in each scan when it sweeps across a band of 
wavelengths and the median wavelength in SS-OCT is 1,050 nm (31). This enables not only 
a scanning speed of 100,000 A-scans per second, but also improved image quality since it 
penetrates the tissue deeper and visualizes the choroidal structures. These features are 
advantageous when studying the vasculature of the retina and choroid with OCT angiography 
(30). This is a novel non-invasive technique that visualizes the vessels by detecting flowing 
red blood cells (32). 
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Figure 3. Image of patient being measured with Canon OCT-HS100. Image published with 
permission from Canon Europe, Amstelveen, Netherlands.  
3.3.3 Retinal images obtained with OCT 
With the technology of SD-OCT, and its improved axial resolution, it is now possible to 
investigate the different layers individually. This is done with intraretinal segmentation 
algorithms which now are incorporated into the software and is performed automatically. 
Before the time of segmentation algorithms, the retinal ganglion cell thickness was studied as 
a total macular volume and not as an individual layer (33). The OCTs of today only requires 
pupil dilation if the pupil diameter is less than 3 mm. Since OCT is depending on optical 
properties of the eye, ocular media opacities, such as cataract or vitreous body opacity, are 
factors that might decrease the signal strength, i.e. loss of image quality (23) 
OCT images are presented either in gray scale (Figure 4) or in color. The more hyper 
reflecting layers will appear brighter than the hypo reflecting layers on the gray scale image 
and different colors will correspond to different degrees of tissue reflectivity on the colored 
image (23). The axonal containing layers, macular RNFL (mRNFL), IPL and OPL, 
backscatters more light than the nuclear layers GCL, INL and ONL and therefore appear 
more hyper reflecting on SD-OCT images (34). Two highly reflective and distinctive layers 
of the outer retina seen in an SD-OCT scan are the ELM and the RPE (35). 
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Figure 4. SD-OCT scan of a normal left eye displayed in gray scale, showing the vitreous, 
retinal layers and choroid. The image was obtained by U. Birkeldh with Canon OCT-HS100. 
3.4 MULTIPLE SCLEROSIS 
3.4.1 An overview of the disease 
MS is a chronic inflammation of the CNS which aims for both gray and white matter (36). It 
affects about 2.5 million individuals worldwide and is the leading cause of non-traumatic 
disability in young adults (37-39). The incidence of MS peaks around 30 years of age (40). 
The overall prevalence in Europe is 83 per 100,000 inhabitants (41). The prevalence in 
Sweden is ~189 per 100,000 inhabitants and is one of the highest in the world (42). There is a 
female preponderance in MS and the female to male ratio reported in Sweden is 2.35:1 (42). 
The etiology is unknown. Both genetic and environmental factors have been proposed to play 
a role in the disease development and progression (38, 43). It is believed that MS outbreak 
derives from interactions between environment and genetics (44). Environmental risk factors 
other than latitude associated with MS are vitamin D status, obesity in childhood, smoking 
and infections (45). Even though MS is not considered to be hereditary there are some genetic 
factors that are known to have a close relationship to MS and might increase the risk of 
disease development (39). About 20% of all MS patients have a relative with the disease and 
the hereditary factor that has been found to have the highest association with MS is the 
human leukocyte antigen (HLA) complex (41, 46). The HLA gene complex on chromosome 
6 is associated with the immune system and this is supporting the theory of MS as an 
autoimmune disease (47, 48). 
The blood-brain barrier (BBB) plays an important role in MS and the disease is thought to 
begin with disruption of the BBB due to acute inflammatory lesions (48). It has been found 
that the BBB might present higher permeability in normal appearing white matter in MS 
patients compared to healthy controls (HCs). This increased passage of leukocytes into the 
CNS leads to demyelination and axonal loss (49). MS is classically thought of as a 
demyelinating disease, but it is also known that the pathology is much more complex. The 
isolating myelin covers of the nerve cells are damaged and become edematous and 
consequently expands the axon diameter in the brain as well as in the spinal cord (50). 
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The chronic disability seen in MS is mainly due to neuro-axonal degeneration rather than 
demyelination (51) and this process seem to occur early in the disease course (52). This 
damage disrupts the communication between cells in the CNS which produces a wide range 
of symptoms.  
Depending on where the lesions are located within the CNS, the symptoms may vary among 
the MS patients (53). The symptoms can include cognitive impairment (such as deficits in 
attention, information-processing speed and impaired memory), changes in sensation 
(numbness and tingling in one or more limbs), muscle weakness, chronic pain, spasms, 
tremor, depression, Lhermitte’s sign (electrical sensation that runs down the spine triggered 
by flexing the head forward) and fatigue among others (38). The overall prevalence of 
cognitive dysfunction in MS has shown to be over 40% and 37% of the cognitively preserved 
MS patients have been reported to develop cognitive dysfunction after four years (54). Vision 
loss is a common first manifestation of MS and is caused by ON. MS might also debut with 
internuclear ophthalmoplegia, which is characterized with impaired eye movements, such as 
diplopia and nystagmus (38). This is due to a lesion involving the medial longitudinal 
fasciculus in the brainstem (55). Uhthoff’s phenomenon is when the symptoms are worsened 
due to increased body temperature (after exercise or a hot bath) and is common among MS 
patients (56). Approximately 30% of all MS patients experience persistent visual 
disturbances, such as visual fatigue, blurred vision, diplopia and visual instability, despite 
wearing glasses. These complaints were not related to a recent MS relapse (57). 
There is no known cure for MS, but there are several treatments. The medications focus on 
slowing disease progression, decrease frequency and severity of relapses and MS related 
symptoms (41). Rehabilitation programs might be a complement to the pharmacological 
treatment and aim to maintain and improve the general health of MS patients (58). Life 
expectancy is 5 to 10 years shorter than that of an unaffected population (53). The diagnosis 
of MS may take many years. There is an international consensus for the use of specific 
criteria that include typical MS lesions in the CNS disseminated in space and time and in a 
combination with the patient’s symptoms or relapses. These revised McDonald criteria from 
2010 are based to a greater extent than before on the MRI findings. This makes it possible in 
some cases to speed the diagnostic process (59). MRI is the gold standard imaging tool for 
brain atrophy in MS. Brain atrophy seen in MS patients has been shown to predict cognitive 
impairment (60).  
3.4.2 Disease subtypes 
A clinically isolated syndrome (CIS) is the first clinical deficit suggestive of MS (61). A 
relapse of MS is an acute inflammatory event in the CNS that leads to a neurological 
symptom in the absence of an infection or fever and persists for at least 24 hours (41, 62). 
About 85% of the patients are initially diagnosed with the disease course of relapsing 
remitting MS (RRMS) (62, 63). This non-progressive type is characterized with relapses that 
may last from a few days to several weeks and are followed by full or partial recovery (64). 
Years after onset many of initially RRMS patients often converts into secondary progressive 
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MS (SPMS) with an increase in disability because of poor functional recovery (41). About 
10-15% of the patients are diagnosed with a primary progressive form of MS (PPMS) at the 
time of disease onset. PPMS is characterized with an on-going accumulation of functional 
disability, especially associated with lesions in the spinal cord, without any typical relapses 
from the very beginning of the disease (63, 65). PPMS has an incidence that is similar among 
males and females. The different subtypes are presented in Figure 5. 
 
 
Figure 5. A graph illustrating the different subtypes of multiple sclerosis with inspiration 
from Hillert et al. (66). Illustration: U. Birkeldh. 
3.4.3 Optic neuritis 
ON has a close relationship to MS and is the first manifestation in 25% of all cases and 70% 
of all patients will at some point during the illness experience an episode of ON (67). 
Approximately 50% of all patients with ON will develop MS within 15 years after ON onset 
(68). It is a demyelinating inflammation of the optic nerve and is usually unilateral. 
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Sometimes abnormalities of the optic nerve are found in the absence of ocular symptoms in 
MS patients. This structural change might be explained by subtle subclinical events of ON 
that does not result in clinically obvious ON (69). The typical symptoms patients report is 
reduced visual acuity, retrobulbar pain especially during eye movements, dyschromatopsia 
and reduced contrast sensitivity (70, 71). The vision loss might span from mild to severe and 
progresses the first 1-2 weeks after onset (70). Important clinical signs are relative afferent 
pupillary defect and visual loss, usually with a central scotoma (72). 
ON is divided into retrobulbar neuritis and the less common papillitis (67). Retrobulbar 
neuritis is an inflammation of the optic nerve behind the globe and therefore initially the 
fundus exam appears normal. Papillitis presents with swelling of the optic disc due to the 
intraocular inflammation (72). Optic disc pallor usually develops 4-6 weeks after ON onset. 
Also, an initial quick recovery begins at this timepoint followed by a slower process and the 
final visual improvement might not be stabilized until one year after onset (73, 74). A 
statistically significant decrease in pRNFL thickness after ON compared with the unaffected 
fellow eye has been shown even in patients who demonstrated good visual recovery. 
However, a larger pRNFL loss correlates with less complete visual function recovery (75). 
High-contrast visual acuity testing is considered an insensitive functional test in ON 
compared to other measures (75-77). It has been found that MS patients with normal high-
contrast visual acuity have reduced pRNFL thickness compared to HCs. However, in the 
same MS patient cohort it was found that this loss of pRNFL thickness correlates well with 
reduced scores in low-contrast visual acuity (76). Gabilondo et al. demonstrated that a loss of 
≥ 4.5 µm in the ganglion cell-inner plexiform layer (GCIP) one month after ON onset 
predicts poor recovery of low-contrast visual acuity six months after onset (78). 
3.5 THE UTILITY OF OCT IN MS 
The usefulness of OCT in MS has been discussed for more than a decade. It is still unknown 
whether any of the retinal layers is superior to the others when distinguishing MS patients 
from HCs. Early MS-OCT studies used TD-OCT and reported thinning of pRNFL thickness 
and/or macular volume loss compared with HCs (76, 79, 80). Petzold et al. have reported two 
comprehensive meta-analyzes regarding retinal layer quantification using OCT (3, 81), the 
first with TD-OCT and the recently published paper included only SD-OCT. The pRNFL 
data found for the SD-OCT was very similar to the previous TD-OCT data. This finding 
accentuates the pRNFL as a precise measure for measuring the neurodegeneration in MS. In 
the SD-OCT meta-analysis they also reported atrophy of the mRNFL and GCIP, but no 
atrophy was found in the INL (81). A large histopathological study with 82 MS patients, by 
Green et al., found that INL atrophy was only found in eyes of patients who had longstanding 
disease and that INL atrophy was associated with the severity of GCIP loss (82). Microcystic 
macular edema, measured with OCT, has been found in MS patients with ON history and it 
was mostly seen in the INL (83). Retinal inflammation, which might be the underlying cause 
of the INL thickness increase, has been found in MS patients with more active disease 
activity (80, 81). 
  21 
It has been suggested that thinning of the retinal layers begin early in the disease (52). 
Atrophy of the retinal layers found with OCT in patients without previous ON could be 
explained either by subclinical ON that might have gone unnoticed or by primary retinal 
pathology related to MS (84). Another suggested explanation for retinal atrophy without ON 
history is retrograde trans-synaptic degeneration (84-86). This is a process when neuronal 
damage is spread backwards through the synapses from a sick neuron to a healthy neuron. 
Klistorner et al. reported that the optic radiations, measured with MRI, are often injured in 
MS patients without ON history and pRNFL thickness, measured with OCT, is significantly 
reduced in these eyes (87). Several other studies have also shown a correlation between 
different MRI brain atrophy markers and OCT parameters of retinal degeneration the past ten 
years (88-92). Saidha et al. reported a 4-year follow-up study of MS patients with significant 
correlations between GCIP loss and the MRI parameters whole brain atrophy, gray matter, 
white matter and thalamic regions (88). These findings suggest that OCT parameters and MS 
related brain atrophy are linked and therefore OCT measurements might be valuable in this 
patient group. 
3.6 ASSESSMENT SCALES IN MS 
3.6.1 Expanded disability status scale  
The expanded disability status scale (EDSS) is the most commonly used assessment scale for 
quantifying neurological disability in MS. It was developed by the neurologist John Kurtzke 
in 1983 and is a revision of his previous disability status scale from 1955 (93). EDSS 
quantifies the disability in MS in eight functional systems: Pyramidal, cerebellar, brain stem, 
sensory, bowel & bladder, visual, cerebral and other functions. Each functional system is 
assigned with a score on a scale that ranges from 0 to 10 in half points. The higher the 
number is, the greater the disability is (0 = no disability, 10 = death due to MS) (93). Just by 
looking at the EDSS score the examiner gets a rough idea of the function level of the patient. 
EDSS score 4.0 indicates maximum walking distance of 500m. EDSS score higher than 4.5 
are defined by the impairment to walking. EDSS has been criticized for its high inter-rater 
variability and for mostly emphasizing the walking ability and barely evaluating the arms or 
cognitive dysfunction. 
3.6.2 Symbol digit modalities test  
The symbol digit modalities test (SDMT) is a screening test for cerebral dysfunction in both 
children and adults. It is based on neuropsychological principles and is very simple to 
perform and administrate (94). SDMT is widely used for screening cognitive impairment in 
patients with MS (95, 96). SDMT measures information processing speed and it takes 
approximately 5 minutes to perform (97). The task is based on the conversion of randomized 
geometric figures into numbers. The correct number corresponding to a specific figure is 
presented for the patient in a key containing the numbers 1 to 9. The test can be performed 
either written or oral to overcome different physical dysfunctions, such as motor handicaps or 
speech disorders (94).  
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3.6.3 Multiple sclerosis impact scale 29 
Self-report scales are frequently used measures of MS and give the patients’ perspective of 
the disease. The multiple sclerosis impact scale (MSIS-29) was developed in 2001 and is 
commonly used (98). This patient-based rating scale consists of 29 questions of which 20 
concerns the physical impact and nine the psychological impact of MS. Each question has 
five options where the patient grades the impact of MS in his/her daily life (1 = not at all; 5 = 
extremely). The score for physical and psychological can be presented both separately and as 
a combined score. 
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4 MATERIALS AND METHODS 
4.1 MATERIAL/DATA COLLECTION 
In paper I subjects were recruited in the outpatient clinic at the Unit of Optometry, St. Erik 
Eye Hospital, Stockholm. Only subjects without any ocular pathology were included in the 
study. Exclusion criteria were history or evidence of macular disease, neurologic disease, 
glaucoma, media opacities, poor OCT image quality and a history of ocular trauma. Only the 
right eye of each subject was included. Thirty subjects (mean age 35.3 years, range 22-66 
years, female/male ratio 24/6) were enrolled. 
In paper II and III the MS patients were recruited when coming to their annual routine 
examination (Paper II: May 2013-October 2015; Paper III: May 2013-May 2016) at the 
Neurology Clinic, Neuro Centrum, Karolinska University Hospital, Solna. A total of 465 MS 
patients were enrolled in paper II and 546 MS patients participated in paper III. All included 
patients had a diagnosis of RRMS, SPMS or PPMS. They were excluded if they had an 
episode of ON during the last 6 months, other neurological disorders or ocular diseases that 
might influence the outcome measures. Disease duration, treatments and ON history were 
recorded. ON history was confirmed from medical records or by patient self-reports. 
In paper II and III a group of HCs were enrolled to age and sex match the MS group. The 
HCs consisted of both subjects from Paper I, staff at St. Erik Eye Hospital, optometry 
students and their family members. The same inclusion and exclusion criteria from paper I 
were used. One hundred sixty-eight healthy subjects (42.3 ± 15.4 years, female/male ratio 
129/39) were enrolled in paper II and one hundred seventy-five healthy subjects (42.5 years ± 
15.4, female/male ratio 134/41) in paper III. All HCs underwent an ophthalmologic 
examination prior to inclusion.  
4.2 METHODS 
Paper I was designed to evaluate the test-retest reliability for the Canon OCT-HS100 and 
Zeiss Cirrus HD-OCT 5000 in healthy subjects, using the new automatic eye tracking 
function. The Canon OCT-HS100 with software version 4.0 (Canon Europe, Amstelveen, 
Netherlands), which performs up to 70,000 A-scans per second with an axial resolution of 
3 µm. It has a scanning depth of 2 mm. The scan mode “Disc 3D” was used to analyze optic 
nerve head and the surrounding pRNFL, see Figure 6. It measures an area of 6x6 mm with 
256 B-scans each consisting of 512 A-scans. The scan diameter circle is 3.45 mm centering 
on the optic disc. The macular measurements were performed within a 10x10 mm area using 
the “Macula 3D” scan mode, which has 128 B-scans, each consisting of 1,024 A-scans. The 
Cirrus HD-OCT 5000 (Carl Zeiss Meditec, Inc., Dublin, California, USA) has an A-scan 
velocity of 27,000 scans per second with an axial resolution of 5 µm and scanning depth of 
2 mm. The optic nerve head and pRNFL measurements were performed with scan mode 
“Optic Disc Cube”, which acquires 200 B-scans, each composed of 200 A-scans. The scan 
circle has a diameter of 3.46 mm and is centered on the optic disc. Measurements of the 
macular area were obtained with “Macular Cube” which has a scan pattern of 128 B-scans, 
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each composed of 512 A-scans. Both “Optic Disc Cube” and “Macular Cube” measures 
within a 6x6 mm area.  
Each subject was measured twice with each OCT, without the use of mydriatic drops, within 
one hour and re-seated before the second scan. One OCT operator was responsible for the 
Canon (P.F.A.) and one for the Zeiss instrument (U.B.).  
 
Figure 6. The report view of “Disc 3D” with the optic disc parameters. Image obtained by U. 
Birkeldh with Canon OCT-HS100 (version 4.00). 
A total of nine optic disc parameters were analyzed for both instruments: Disc area, rim area, 
cup volume, vertical cup/disc ratio, pRNFL thickness in the four quadrants (inferior, superior, 
nasal and temporal) and the overall average pRNFL thickness 360° around the optic nerve 
head. For the macular measurements the thickness value in each of the nine subfields 
corresponding to the Early Treatment of Diabetic Retinopathy Study (ETDRS) were 
analyzed, see Figure 7. 
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Figure 7. The nine subfields of macular thickness corresponding to the Early Treatment of 
Diabetic Retinopathy (EDTRS). Image obtained by U. Birkeldh from the report view of 
“Macula 3D” with Canon OCT-HS100. 
Paper II was designed to cross-sectionally investigate the pRNFL thickness in all MS 
subtypes compared to HCs and to find possible correlations between pRNFL and different 
neurological clinical measures. SD-OCT measures were performed using the same Canon - 
HS100 with software version 4.0 from paper I. The scan mode “Disc 3D” was used for the 
pRNFL measurements in both MS patients and HCs. The thickness values analyzed were the 
four quadrants (inferior, superior, nasal and temporal) and the overall average value of the 
whole pRNFL 360° around the optic nerve head.  
In paper III possible correlations between the average pRNFL, temporal RNFL (T-pRNFL), 
macular thickness and different clinical outcomes in MS patients were evaluated. Both “Disc 
3D” and “Glaucoma 3D” were performed and with the same Canon OCT-HS100 (software 
version 4.2.0) as in paper I and II. The “Glaucoma 3D” was used for the measurements 
around the fovea and is composed of 128 B-scans each consisting of 1,024 A-scans. This 
macular scan mode measures the thickness over a 10x10 mm area which is centered on the 
fovea. The thickness map is composed of one inner ring (the area bounded by the central 
circle of 1.5 mm diameter and the middle circle of 5 mm diameter) and one outer ring (the 
area bounded by the middle circle of 5 mm diameter and the outer circle of 10 mm diameter), 
each with four subfields (Figure 8). For both the inner and outer ring, the thickness of 
macular retinal nerve fiber layer + macular ganglion cell layer + macular inner plexiform 
layer complex (GCC) is obtained. The GCIP thickness was also obtained from this thickness 
map. Segmentation of the retinal layers was acquired automatically using the incorporated 
segmentation software.  
In paper II and III the physical disability was assessed with EDSS by an experienced 
neurologist. Cognitive impairment was assessed with SDMT by one of the MS nurses. MSIS-
29 was used to measure the physical and psychological impact of MS from the patient’s point 
of view. These measurements were collected from the Swedish MS register and performed 
during the patients’ routine visit.  
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The measurements were obtained from both eyes in normal daylight conditions of each 
patient in a single session with the same device and replicated three times. Measurements 
were performed on both the MS group and HCs, primarily by the same examiner (U.B.). The 
pupils were not dilated before OCT measurements. All images were checked manually 
afterwards for artefacts and adequate signal strength ≥7 (maximum, 10). Further quality 
assessment was performed according to the OSCAR-1B criteria (99) and the Advised 
Protocol for OCT Study Terminology and Elements (APOSTEL) recommendations (100). 
The scan with the highest quality was included in the analysis. 
 
 
Figure 8: Illustration of the thickness map around the fovea in scan mode “Glaucoma 3D” 
with SD-OCT Canon HS100, inspired from Ng et al. (101). Printed with permission from the 
illustrator, L. Pettersson. 
4.3 STATISTICS 
In paper I the coefficient of repeatability (CR) for each of all optic disc and macular 
parameters was calculated according to the Bland-Altman method (102). The CR value was 
also calculated as a percentage of the mean (CR%). For each of all OCT parameters the 
squared Pearson correlation coefficient was calculated to determine the relationship between 
first and second measure. The statistical analysis used for the investigation of possible 
differences between the first and second measure was the one-sample t-test for normally 
distributed data. Wilcoxon rank-sum test was used for those measurements when the data was 
not normally distributed. The mean difference for each of all included OCT parameters 
between the two instruments were statistically compared with each other using a one-way 
ANOVA with Tukey post-hoc test. The two OCT’s were also statistically compared 
according to their CR values with a paired t-test. All statistical analyzes were performed 
using Instat™ GraphPad Software Inc. version 3. 
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For paper II, the comparison of overall average pRNFL thickness and the pRNFL thickness 
in each quadrant (inferior, superior, nasal and temporal) between MS subtypes and HCs was 
performed using linear mixed effect models. These analyzes were accounting for within-
patient inter-eye correlations and adjusted for age, sex and previous history of ON. The linear 
mixed effect models within MS were designed to assess the cross-sectional relationship 
between average pRNFL and pRNFL in the four quadrants and EDSS, SDMT and MSIS-29 
(divided in physical and psychological scales). These models were adjusted for age, sex, ON 
history, disease duration, MS subtype and duration of exposure to first and second line 
disease modifying treatments (DMTs). All analyzes were performed using R version 3.3.2 (R 
Core Team, 2016) and package Non-Linear Mixed Effects.  
In paper III, the thicknesses of overall average pRNFL, T-pRNFL, inner ring of GCC (inner 
GCC), outer ring of GCC (outer GCC), inner ring of GCIP (inner GCIP) and outer ring of 
GCIP (outer GCIP) were compared between MS including all subtypes, each MS subtype 
separately and HCs, using generalized estimation equation (GEE) models. The GEE models 
were designed to account for within-subject inter-eye correlations. These models were also 
corrected for age, sex and previous history of ON. For the comparison of MS only, the 
association between the different OCT measures and EDSS, SDMT and MSIS-29 (both 
physical and physiological) was analyzed using GEE models. These models were corrected 
for age, sex, previous ON history, disease duration, MS subtype and duration of exposure to 
DMTs. The number of previous SDMT examinations was taken into account as an additional 
adjustment in the model when the SDMT score was investigated. The analyzes regarding 
OCT measures and their relationship to EDSS, SDMT and MSIS-29 were also performed on 
eyes with no history of ON. This was done to make sure that the statistical correction for ON 
was sufficient enough since previous ON might be significantly different among individuals.  
The predictive value of different baseline OCT measures on the trajectory of consecutive 
SDMT and EDSS scores was evaluated over a 36-month follow-up period. The evaluated 
measures in the longitudinal assessment were baseline average pRNFL, T-pRNFL, inner 
GCC and inner GCIP thicknesses. Measurements were categorized into two groups of 
“reduced” and “normal.” “Normal” OCT measure was defined if the measurement was 
within one standard deviation of the respective measure in HCs. The OCT measure was 
considered “reduced” if the measurement was two or more standard deviations lower than the 
respective measure in HCs. GEE models were applied in the longitudinal analysis and 
corrected for age, sex, previous ON history, MS onset age, MS subtype and duration of 
exposure to DMTs. This was an exploratory analysis so that no correction for multiple 
comparisons was made. All analyzes were performed using R version 3.3.2 (R Core Team, 
2016) and package geepack.  
The significance threshold was set to P < 0.05 in all three studies in this thesis. 
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4.4 ETHICS 
Informed consent was obtained from all participants prior inclusion. The studies were 
approved by the Regional Ethical Review Board in Stockholm (DNR 2009/2107-31/2 and 
2011/874-31/2) and were performed according with the ethical standards stated in the 
Declaration of Helsinki. 
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5 RESULTS 
5.1 PAPER I 
5.1.1 OCT measures within instruments 
The test-retest reliability was good for all analyzed parameters in both OCT’s, according to 
the CR values. The CR% for the optic disc measurements ranged between 0.90% and 22.22% 
and between 0.00% and 16.00% with Canon OCT-HS100 and Zeiss Cirrus HD-OCT 5000 
respectively. Both instruments showed high correlations between the two measurements in 
each of all included parameters, the R2 value ranging from 0.76 to 0.98 for Canon and from 
0.94 to 0.99 with Zeiss. No statistical difference was found between the two measurements 
for any of the parameters in both instruments (p > 0.05). The optic disc measurements within 
each OCT are presented in Table 1. 
Table 1. Repeatability of optic disc parameters. 
 Canon OCT-HS100 Zeiss Cirrus HD-OCT 5000 
 Mean CR CR% R2  p  Mean CR CR% R2 p 
Disc area (mm2) 2.08 
± 0.41 
0.21 10.10 0.92 0.61 1.87 
± 0.35 
0.10 5.34 0.96 0.71 
Rim area (mm2) 1.58 
± 0.37 
0.20 12.66 0.97 0.55 1.41 
± 0.24 
0.08 5.67 0.97 0.97 
Cup volume 
(mm3) 
0.09 
± 0.12 
0.02 22.22 0.98 0.63 0.13 
± 0.12 
0.02 16.00 0.99 0.71 
Cup/Disc vertical 
ratio 
0.48 
± 0.14 
0.05 10.41 0.97 0.99 0.47 
± 0.12 
0.04 8.51 0.96 0.45 
RNFL average 
(µm) 
99.16 
± 8.57 
5.46 5.51 0.93 0.15 93.96 
± 8.95 
3.39 3.61 0.96 0.21 
RNFL Inferior 
(µm) 
127.80 
± 36.47 
1.15 0.90 0.92 0.71 122.86 
± 34.41 
1.09 0.89 0.96 0.61 
RNFL Superior 
(µm) 
118.36 
± 31.43 
2.27 1.92 0.76 0.16 112.57 
± 30.29 
0.89 0.79 0.94 0.68 
RNFL Nasal 
(µm) 
80.52 
± 18.94 
2.09 2.60 0.89 0.15 72.23 
± 17.33 
0.00 0 0.98 0.99 
RNFL Temporal 
(µm) 
69.60 
± 16.03 
1.50 2.16 0.91 0.35 65.11 
± 16.24 
0.89 1.37 0.97 0.53 
RNFL = retinal nerve fiber layer, CR = coefﬁcient of repeatability; CR% = coefﬁcient of repeatability as a 
percentage of mean 
The CR% for the macular measurements were lower than in the optic disc, i.e. the 
repeatability was better in the macula. The values ranged from 0.62 to 2.81% for Canon and 
0.99 to 1.81% for Zeiss. The R2 for the macular region was high and ranged between 0.89 and 
0.99 and 0.93-0.99 with Canon and Zeiss respectively. There was no statistical difference 
between first and second measure in any of the evaluated parameters in both OCT’s (p > 
0.05). Table 2 shows the repeatability for thickness measurements in the macular region 
within each instrument. 
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Table 2. Repeatability of macular measurements. 
 Canon OCT-HS100 Zeiss Cirrus HD-OCT 5000 
Thickness 
(µm) 
Mean CR CR% R2 p Mean CR CR% R2 p 
Center 276.22  
± 15.69 
5.04 1.82 0.97 0.95 259.34  
± 15.97 
2.57 0.99 0.99 0.55 
Inner 
superior 
351.08 
± 12.07 
2.82 0.80 0.98 0.99 324.82 
± 11.48 
5.25 1.62 0.95 0.36 
Inner nasal 352.02 
± 14.13 
3.11 0.88 0.99 0.07 327.27 
± 13.72 
4.28 1.31 0.97 0.36 
Inner inferior 347.33 
± 10.99 
4.46 1.28 0.95 0.71 322.38 
± 11.99 
4.05 1.26 0.97 0.58 
Inner 
temporal 
335.34 
± 10.82 
2.09 0.62 0.99 0.90 311.41 
± 10.57 
4.20 1.35 0.96 0.15 
Outer 
superior 
305.21 
± 12.17 
8.58 2.81 0.89 0.16 277.65 
± 12.42 
6.65 1.67 0.96 0.38 
Outer nasal 317.66 
± 14.57 
2.98 0.94 0.99 0.29 295.48 
± 14.24 
3.57 1.21 0.98 0.44 
Outer 
inferior 
290.74 
± 12.22 
4.80 1.65 0.97 0.35 267.27 
± 14.21 
3.73 1.40 0.98 0.26 
Outer 
temporal 
287.54 
± 10.17 
4.00 1.39 0.96 0.69 258.96 
± 9.55 
4.70 1.81 0.93 0.50 
CR = coefﬁcient of repeatability; CR% = coefﬁcient of repeatability as a percentage of mean 
5.1.2 Between instrument comparison 
For the optic disc measurements, the R2 values ranged between 0.66 and 0.97, however there 
was no statistical difference in CR values between Canon OCT-HS100 and Zeiss Cirrus HD-
OCT (p > 0.05). For the OCT-derived thickness measures in the macula, R2 ranged between 
0.43 and 0.96 and there was a statistical difference in thickness values between the two 
instruments (p < 0.05). Canon measured thicker values for all macular parameters compared 
with Zeiss (Table 3). 
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Table 3. Comparison in repeatability between Canon OCT-HS100 and Zeiss Cirrus HD-
OCT 5000. Positive values and negative values imply greater/thicker measurements and 
lower/thinner measurements with Canon respectively. 
Optic disc Mean difference (p-value) R2 (p-value) 
Disc area (mm2)  0.22 (p > 0.05) 0.80 (p < 0.05) 
Rim area (mm2)  0.17 (p > 0.05) 0.73 (p < 0.05) 
Cup volume (mm3) -0.03 (p > 0.05) 0.97 (p < 0.05) 
Cup/Disc vertical ratio -0.03 (p > 0.05) 0.85 (p < 0.05) 
RNFL average (µm)  5.20 (p > 0.05) 0.87 (p < 0.05) 
RNFL Inferior (µm)  5.36 (p > 0.05) 0.82 (p < 0.05) 
RNFL Superior (µm)  5.43 (p > 0.05) 0.67 (p < 0.05) 
RNFL Nasal (µm)  8.02 (p > 0.05) 0.69 (p < 0.05) 
RNFL Temporal (µm)  4.00 (p > 0.05) 0.66 (p < 0.05) 
Macula   
Center (µm) 16.87 (p < 0.05) 0.96 (p < 0.05) 
Inner superior (µm) 26.25 (p < 0.05) 0.43 (p < 0.05) 
Inner nasal (µm) 24.74 (p < 0.05) 0.62 (p < 0.05) 
Inner inferior (µm) 24.95 (p < 0.05) 0.53 (p < 0.05) 
Inner temporal (µm) 23.93 (p < 0.05) 0.67 (p < 0.05) 
Outer superior (µm) 27.55 (p < 0.05) 0.59 (p < 0.05) 
Outer nasal (µm) 22.18 (p < 0.05) 0.60 (p < 0.05) 
Outer inferior (µm) 23.46 (p < 0.05) 0.62 (p < 0.05) 
Outer temporal (µm) 28.58 (p < 0.05) 0.64 (p < 0.05) 
RNFL = retinal nerve fiber layer 
5.2 PAPER II  
5.2.1 Comparison of pRNFL parameters between MS subtypes and HCs 
The average pRNFL thickness and pRNFL thickness in the four quadrants around the optic 
nerve head were compared between MS eyes and eyes of HCs. The group of HCs were set as 
reference in the analysis. The total MS cohort of 465 patients was divided into subtypes and 
consisted of 336 RRMS (72%), 112 (24%) SPMS and 17 (4%) PPMS patients. The 
demographics of study participants is presented in Table 4. A statistically significant 
thickness loss, compared with HCs, was seen in all MS subtypes and in all pRNFL 
parameters except in the superior quadrant of PPMS. The average pRNFL was 6.4 µm 
thinner (95% CI -8.5 to -4.3 µm, p < 0.001) in RRMS, 11.6 µm thinner (95% CI -14.4 to -8.8 
µm, p < 0.001) in SPMS and 10.7 µm thinner (95% CI -16.0 to -5.5 µm, p < 0.001) in PPMS 
compared to HCs. A significantly thinner pRNFL thickness was seen in all quadrants in 
RRMS and SPMS. The largest thickness difference compared to HCs was found in the T-
pRNFL of PPMS patients with a mean reduction of 15.8 µm (95% CI -21.4 to -10.1 µm). 
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Table 4. Demographics of study participants. 
 HCs 
(n=168) 
RRMS 
(n=336) 
SPMS 
(n=112) 
PPMS 
(n=17) 
Age at OCT date (mean ± SD) 42.3 ± 15.4 38.9 ± 9.7 53.8 ± 10.0 50.2 ± 13.2 
Sex (% female) 76.7  70.8  65.4 55.6 
Disease duration (mean years ± SD)  9.1 ± 7.2 21.8 ± 9.4 10.6 ± 8.3 
Disease modifying treatment duration 1st line 
(mean years ± SD) 
 2.8 ± 37 5.6 ± 6.3 2.5 ± 5.0 
Disease modifying treatment duration 2nd line 
(mean years ± SD) 
 1.4 ± 2.1 1.3 ± 2.3 0.2 ± 0.4 
EDSS median (interquartile range)  2.0 (1.5) 5.5 (2.8) 5.5 (2.0) 
% of eyes with previous  
history of ON in one eye 
 87 (26.5%) 24 (18.9%) 0 (0%) 
% of eyes with previous  
history of ON in both eyes 
 23 (6.2%) 8 (6.3%) 0 (0 %) 
HCs = healthy controls, RRMS = relapsing remitting multiple sclerosis, SPMS = secondary progressive multiple 
sclerosis, PP = primary progressive multiple sclerosis, OCT = optical coherence tomography, EDSS = expanded 
disability status scale, ON = optic neuritis 
5.2.2 Comparison of average pRNFL thickness in eyes with and without ON 
history and HCs 
MS eyes with history of ON (MSON+) had the most reduced pRNFL thickness with an 
average of 80 µm. MS eyes without prior ON (MSON-) showed similar thickness values as 
the unaffected fellow eye of MSON+ (93 µm versus 94.5 µm). HCs had an average pRNFL 
thickness of 99 µm. 
5.2.3 Association between pRNFL parameters and physical and cognitive 
dysfunction 
A statistical association was found between EDSS and average pRNFL (p < 0.01) and T-
pRNFL (p < 0.01) thicknesses. For every increase in EDSS score, i.e. increased neurological 
disability, the average pRNFL was reduced by 1.0 µm (95% CI -1.7 to -0.2) and the T-
pRNFL thickness decreased by 1.2 µm (95% CI -2.0 to -0.5). A borderline association was 
found between EDSS and the inferior quadrant of pRNFL (-1.2 µm (95% CI -2.3 to 0.0; p < 
0.05)). No statistical relationship was found between EDSS and pRNFL thickness in the 
superior and nasal quadrants. A statistically significant relationship was mainly found 
between SDMT score and the T-pRNFL quadrant. The T-pRNFL was reduced by 0.2 µm 
(95% CI 0.1 to 0.3; p < 0.01) with every point of decrease in SDMT score, i.e. worsening of 
cognition (Table 5). No statistical association could be found between MSIS-29 physical or 
psychological scores and any of the pRNFL parameters.
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Table 5. Peripapillary retinal nerve fiber layer thickness difference between multiple sclerosis subtypes and healthy controls. The relationship between 
optical coherence tomography measures and clinical assessment scales are shown. The values in the boxes of the assessment scales include the entire 
multiple sclerosis cohort and reflect best-fit slopes with units of microns/scale points. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCs = healthy controls, RR = relapsing remitting, SP = secondary progressive, PP = primary progressive, EDSS = expanded disability status scale, SDMT = symbol digit modalities test, 
MSIS-29 = multiple sclerosis impact scale 29 † Adjusted for age, sex and previous history of optic neuritis. ǂ Only MS patients were included and a correction for MS subtype, disease 
duration, age, sex, duration of exposure to disease modifying treatments was done. * For p < 0.05, ** for p < 0.01, and *** for p < 0.001 
 
 Peripapillary retinal nerve fiber layer thickness difference (µm) 
  Average 
Quadrants 
Superior Nasal Inferior Temporal 
Disease subtype † 
HCs 
RR 
SP 
PP 
 
Ref. 99 µm ± 9.7 
-6.4 (-8.5 to -4.3) *** 
-11.6 (-14.4 to -8.8) *** 
-10.7 (-16.0 to -5.5) *** 
 
Ref. 120 µm ± 13.8 
-5.5 (-8.3 to -2.7) *** 
-11.2 (-19.0 to -8.4) *** 
-4.7 (-11.9 to 2.4) 
 
Ref. 83 µm ± 14.7 
-5.9 (-10.5 to -3.9) *** 
-8.1 (-18.9 to -10.2) *** 
-10.7 (-18.9 to 2.3) *** 
 
Ref. 127 µm ± 16.6 
-7.2 (-10.5 to -3.9) *** 
-14.5 (-18.9 to -2.3) *** 
-10.6 (-18.9 to -2.3) * 
 
Ref. 71 µm ± 11.1 
-7.6 (-9.8 to -5.3) *** 
-13.2 (-16.2 to -10.3) *** 
-15.8 (-21.4 to -10.1) *** 
EDSS ǂ -1.0 (-1.7 to -0.2) **  -0.8 (-1.8 to 0.2)  -0.7 (-1.5 to 0.1) -1.2 (-2.3 to 0.0) * -1.2 (-2.0 to -0.5) ** 
SDMT ǂ  0.1 (0.0 to 0.2) *  0.1 (0.0 to 0.2)  0.0 (-0.1 to 0.1)  0.2 (0.0 to 0.3) *  0.2 (0.1 to 0.3) ** 
MSIS-29 ǂ 
Physical Scale 
Psychological Scale 
 
-0.30 (-1.71 to 1.10) 
 0.1 (-1.12 to 1.35) 
 
-0.5 (-2.33 to 1.36) 
-0.1 (-1.68 to 1.55) 
 
 0.1 (-1.45 to 1.69) 
-0.1 (-1.45 to 1.30) 
 
-0.9 (-3.07 to 1.30) 
 0.3 (-1.65 to 2.19) 
 
0.1 (-1.35 to 1.47) 
0.4 (-0.79 to 1.68) 
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5.3 PAPER III 
5.3.1 Comparison of OCT parameters between MS patients and HCs 
Demographics of the 546 MS patients and 175 HCs are presented in Table 6. Most MS 
patients had RRMS (72%), followed by SPMS (25%) and PPMS (3%). Seventy percent of 
the MS cohort and ~76% of the HCs were female. The progressive types of MS showed 
significantly higher EDSS scores and significantly lower SDMT scores compared with 
RRMS (p < 0.001 respectively). Approximately 19% of patients with RRMS had a history of 
previous ON in one eye and almost 7% had prior ON in both eyes. In the SPMS group 
approximately 15% had prior ON in one eye and 4% had ON in both eyes. 
All analyzed OCT parameters (average pRNFL, T-pRNFL, inner GCC and inner GCIP 
thicknesses) were significantly reduced in thickness in all MS eyes as a group and in each 
subtype, compared with HCs. However, as shown in Table 7, T-pRNFL and inner GCC had 
strong p-values and the highest regression coefficients in differentiating MS subtypes from 
HCs. The highest regression coefficient was found for the T-pRNFL in PPMS patients with a 
reduction of 16.31 µm (p < 0.001) compared with HCs. 
Table 6. Demographics of study participants. 
 HCs 
(n=175) 
PP 
 (n=19) 
RR  
(n=391) 
SP 
 (n=136) 
Age (mean ± SD) 42.5 ± 15.4 51.8 ± 13.9 38.8 ± 9.5 54.7 ± 10.1 
Sex (% female) 76.6 57.9  70.8 66.9 
Disease duration (mean years ± SD) --- 11.2 ± 7.9 8.8 ± 7.1 22.9 ± 10 
Treatment duration 1st line (mean years 
± SD) 
--- 2.3 ± 4.7 2.7 ± 3.7 5.5 ± 6.1 
Treatment duration 2nd line (mean 
years ± SD) 
--- 0.3 ± 0.6 1.3 ± 2.0 1.2 ± 2.3 
EDSS at baseline, (median (IQR)) --- 6 (2) 2 (1.5) 5.5 (2.5) 
SDMT at baseline, (median (IQR)) --- 50 (11) 57 (15) 47 (27) 
MSIS-29 at baseline, (mean (± SD)) 
Physical scale 
Psychological scale 
---  
2.8 ± 0.8  
2.4 ± 0.9 
 
1.7 ± 0.8 
2.1 ± 0.9  
 
2.7 ± 0.9 
2.5 ± 0.9 
Previous history of ON in one eye, % --- 0  18.8 15.4 
Previous history of ON in both eyes, % --- 0  6.6 4.4 
PP: primary progressive, RR: relapsing remitting, SP: secondary progressive, HCs: healthy controls. 
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Table 7. Average reduction in thickness of optical coherence tomography measures in 19 
primary progressive (PP), 391 relapsing remitting (RR) and 136 secondary progressive (SP) 
multiple sclerosis patients compared with 175 healthy controls (HCs).  
 
Average pRNFL 
(µm) 
T-pRNFL (µm) Inner GCC (µm) Inner GCIP (µm) 
HCs Ref. P-value Ref. P-value Ref. P-value Ref. P-value 
MS All 
subtypes 
-7.58 < 0.001 -9.35 < 0.001 -8.24 < 0.001 -6.31 < 0.001 
RR -6.29 < 0.001 -7.74 < 0.001 -6.38 < 0.001 -4.97 < 0.001 
SP -11.29 < 0.001 -13.07 < 0.001 -12.79 < 0.001 -9.81 < 0.001 
PP -9.18    0.009 -16.31 < 0.001 -12.16 < 0.001 -7.86 < 0.001 
pRNFL: peripapillary retinal nerve fiber layer; T-pRNFL: temporal peripapillary retinal nerve fiber layer; GCC: 
ganglion cell complex, GCIP: ganglion cell–inner plexiform layer. Coefficient from generalized estimation 
equation models adjusted for age, sex, and previous history of optic neuritis. 
5.3.2 Association between OCT parameters and physical and cognitive 
dysfunction 
Physical disability as measured with EDSS was associated with all four OCT measures after 
controlling for potential confounders including MS subtype, sex, age, disease duration, 
previous ON history, and duration of DMTs. The highest regression coefficient was seen in 
the inner GCC with a reduction of 1.78 µm (p < 0.001) for every increased EDSS score. Inner 
GCC was followed by T-pRNFL and inner GCIP with a reduction of 1.52 μm (p < 0.001) and 
1.28 μm, (p < 0.001), respectively. Higher SDMT scores, i.e. better cognitive performance, 
were associated with greater thicknesses in all four OCT measures. The OCT measure 
showing highest association with SDMT was T-pRNFL thickness with a regression 
coefficient of 0.17 μm (p < 0.001). The analysis including only MS eyes without prior ON 
did not influence the results for neither EDSS or SDMT. No statistical association could be 
found between MSIS-29 physical or psychological scores and any of the OCT measures 
(Table 8). 
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Table 8. The association between baseline OCT-derived thickness measures of MS eyes, 
including the entire MS group, and different assessment scales.  
All eyes (Models 
are adjusted for 
previous history of 
optic neuritis) 
Average pRNFL 
thickness (µm) 
Temporal 
pRNFL 
thickness (µm) 
Inner GCC 
thickness (µm) 
Inner GCIP 
thickness (µm) 
EDSS score  -1.08 P < 0.001 -1.27 P < 0.001 -1.77 P < 0.001 -1.32 P < 0.001 
SDMT score   0.14 P = 0.001  0.16 P < 0.001 0.11 P = 0.02  0.07 P = 0.04 
MSIS-29 Physical 
scale  
-0.34 P = 0.64  0.15 P = 0.83 -1.03 P = 0.16 -0.88 P = 0.11 
MSIS-29 
Psychological scale  
 0.16 P = 0.81  0.55 P = 0.37 -0.59 P = 0.36 -0.66 P = 0.17 
In eyes with no 
history of optic 
neuritis 
Average pRNFL 
thickness (µm) 
Temporal 
pRNFL 
thickness (µm) 
Inner GCC 
thickness (µm) 
Inner GCIP 
thickness (µm) 
EDSS score  -1.06 P = 0.006 -1.52 P < 0.001 -1.78 P < 0.001 -1.28 P < 0.001 
SDMT score  0.14 P = 0.001  0.17 P < 0.001 0.12 P = 0.02  0.08 P = 0.05 
EDSS: expanded disability status scale, SDMT: symbol digit modalities test, MSIS 29 = multiple sclerosis 
impact scale 29, pRNFL: peripapillary retinal nerve fiber layer; T-pRNFL: temporal peripapillary retinal nerve 
fiber layer; GCC: ganglion cell complex, GCIP: ganglion cell–inner plexiform layer. 
5.3.3 Longitudinal analysis of OCT parameters and future disability 
worsening 
The patients with reduced OCT thickness had an average of 0.7 EDSS (0.51-0.87) scores 
higher than the patients with normal OCT thickness over the 36-month follow-up time and 
the results were statistically significant. Also, the patients with reduced OCT thickness 
performed with an average of 4.4 (4.1-4.9) SDMT scores lower than the patients with normal 
OCT thickness during the follow-up time and the difference was statistically significant. 
Overall, it was not possible to predict future physical disability and/or cognitive impairment 
since patients with reduced or normal baseline OCT thickness were almost parallel over the 
follow-up time in both EDSS and SDMT (Figures 9 and 10). 
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Figure 9. Progression of physical disability measured with expanded disability status scale 
(EDSS) according to baseline optical coherence tomography (OCT) measures over a 36-
month period: A.) Inner ganglion cell complex (GCC), B.) Inner ganglion cell-inner 
plexiform layer (GCIP), C.) Average peripapillary retinal nerve fiber layer (pRNFL), 
D.) Temporal peripapillary retinal nerve fiber layer (Temporal pRNFL). “Normal” values for 
each OCT measure was defined as within one standard deviation of each measure in healthy 
control eyes and “reduced” was two or more standard deviations lower than healthy control 
eyes. 
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Figure 10. Progression of cognitive impairment measured with symbol digit modalities test 
(SDMT) according to the baseline optical coherence tomography (OCT) measures over a 36-
month period: A.) Inner ganglion cell complex (GCC), B.) Inner ganglion cell-inner 
plexiform layer (GCIP), C.) Average peripapillary retinal nerve fiber layer (pRNFL), 
D.) Temporal peripapillary retinal nerve fiber layer (Temporal pRNFL). “Normal” values for 
each OCT measure was defined as within one standard deviation of each measure in healthy 
control eyes and “reduced” was two or more standard deviations lower than healthy control 
eyes. 
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6 DISCUSSION 
The overall purpose of the three studies this thesis is based on was to investigate the 
potentials of OCT as a non-invasive tool for monitoring MS patients and measuring physical 
disability and cognitive impairment. Because of the recently developed segmentation 
algorithms, which are incorporated into the OCT, it is possible to automatically quantify the 
thickness of different retinal layers. Since the usefulness of an instrument depends strongly 
on its test-retest reliability it was important to firstly evaluate the new Canon-OCT HS100 
with its automatic eye tracking function and compare it with the well-established Zeiss Cirrus 
HD-OCT 5000. The automatic eye track system remembers the previous scan area on the 
retina and will automatically position on the same location during follow-up examinations. 
To have each image at the exact location is a big advantage when monitoring progression of 
retinal pathologies and when comparing scans from previous examinations, such as 
monitoring retinal thickening over time. This automatic system makes the scan procedure 
quicker and easier for the operator since it immediately recovers its position on the retina if 
the patient blinks or changes fixation. In Paper I the optic disc and macular parameters were 
found to be repeatable in both instruments, however slightly better with the Zeiss Cirrus HD-
OCT. The CR% range decreased in both OCTs when the cup volume parameter was 
excluded. The cup volume was also the least repeatable parameter in our previous study with 
the same OCTs (103). The CR% values of the macular parameters for both OCTs had a 
smaller range than the optic disc parameters, i.e. the variation was less, and the repeatability 
was better in the macular region than in the optic disc. This probably has an anatomical 
explanation. Unlike the macular region, the appearance of the optic disc often varies a lot 
among individuals. The presence of blood vessels may interfere the optic disc measurements. 
This makes it more difficult to identify the structures properly and the variation increases 
(104). In addition, tilted disc and peripapillary crescent, which are common features among 
myopes, might also influence the measurements since it might be difficult for the OCT to 
correctly define the optic disc margin. It is difficult to compare measurements obtained from 
different OCTs because of different wavelengths, scan speed and axial resolution. With 
higher resolution it is more difficult to replicate the segmentation. This might explain why the 
repeatability is slightly better with Zeiss, which has lower resolution than Canon.  
Although the correlation between Canon-OCT HS100 and Zeiss Cirrus HD-OCT was good, 
the thickness estimation was different between the two instruments. This is in line with a 
previous study investigating macular thickness with six different OCTs, including Cirrus HD-
OCT, in healthy subjects (105). Canon-OCT HS100 reported slightly thicker values than 
Zeiss Cirrus HD-OCT in almost all the evaluated parameters, especially in the macular 
region. Only the cup volume and cup/disc vertical ratio values were larger with the Zeiss 
Cirrus HD-OCT. This difference in quantitative estimation between different OCTs is 
important to have in mind when interpreting the results. It is therefore necessary to use the 
same device when monitoring a patient over time, i.e. OCTs are not interchangeable. Smaller 
disc scan diameter increases the risk of measuring close to the optic nerve head border which 
is an area with thicker pRNFL (106). This might explain why Canon, with slightly smaller 
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disc scan diameter than Zeiss (3.45 mm vs. 3.46 mm), gave rise to thicker pRNFL values. 
The macular thickness measurements were approximately 24 µm thicker when measured 
with Canon. This is most likely explained by the differences in the segmentation software for 
the instruments, i.e. different reference planes are used (105). Canon defines the retinal 
thickness from ILM to the outer border of RPE whereas Zeiss measures the thickness from 
ILM to the center of the RPE layer.  
In paper II and III the purpose was to investigate the thickness of different OCT measures in 
all MS subtypes compared with HCs and to correlate these measures with functional tests. 
Paper II focused on the pRNFL thickness, which was the retinal structure that was initially 
investigated in MS-OCT studies. However, most studies have included small cohorts and/or 
not included all MS subtypes. In addition, many studies applied the older generation of OCT. 
Both paper II and III present large single-center cohorts with all MS subtypes included. To 
the best of our knowledge, only the study by Gelfand et al. have had a larger single-center 
MS cohort (52). Regarding pRNFL, in paper III we chose to focus on the overall average 
value and T-pRNFL and did not analyze the other quadrants. This was based on our results 
from paper II. Some patients find it very difficult to fixate on the target during the optic disc 
image acquisition and this can make it difficult to obtain high quality images. Therefore, it 
was interesting to investigate if the thickness reduction in the macular region of MS patients 
differed from the HCs as much as T-pRNFL. Due to the newly developed segmentation 
algorithms it was possible to automatically quantify the macular GCIP and macular GCC 
thicknesses. In paper III we also investigated the predictive value of baseline OCT measures 
over a 36-month period. 
The effect of previous ON on pRNFL thickness was evaluated in paper II. MSON+ eyes had 
approximately 20 µm reduction of pRNFL thickness compared to HCs. This finding is in 
accordance with previous studies and was not surprising since it is well established that ON 
has a great impact on pRNFL (3, 79, 81). It has been discussed that the MSON+ eye might 
influence the pRNFL of the fellow eye. This is caused by the ON lesion in the MSON+ eye 
spreading into the chiasm leading to pRNFL thinning of the fellow eye (87). It is not well 
described in the literature how much the pRNFL in the fellow eye of MSON+ eye might be 
reduced. To investigate this, we separated the fellow eyes without ON history and compared 
the mean thickness values between the groups. The MSON+ fellow eye was shown to have a 
similar pRNFL thickness reduction as MSON- eyes. In other words, a reduction was seen in 
the fellow eyes of MSON+ eyes, however the thinning was not larger than in the MS patients 
without ON history in either eye. ON within 6 months prior to OCT assessment was an 
exclusion criterium in our analyzes. This is common feature in MS-OCT studies since the 
retinal atrophy following an ON attack is not stabilized until 6 months after onset (75, 107). 
The pRNFL is also known to swell during an on-going ON and the true reduction might be 
masked due to initial edema in the acute phase (first 3 months). The macular GCIP has been 
proposed to be superior to pRNFL for early detection of retinal atrophy in acute ON since it is 
not influenced by edema (78, 108, 109). 
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Except for the superior quadrant of PPMS, paper II showed a statistically significant thinning 
of pRNFL for all MS subtypes compared with HCs and this is in agreement with previous 
publications (52, 79, 110). Although all quadrants were reduced in thickness compared with 
HCs, they were not equally affected. The average pRNFL is calculated from the average 
values of each quadrant. This might weaken an existing association and average pRNFL is 
therefore not the most sensitive pRNFL parameter. The largest pRNFL thickness reduction 
compared with HCs was seen in the T-pRNFL of PPMS with an average decrease of 15.8 
µm. In paper III we reported that both pRNFL and GCIP thickness were reduced in MS 
patients compared to HCs, which is in line with other studies (111-113) and that the T-
pRNFL was the most reduced parameter in all MS subtypes. The largest reduction was found 
in PPMS patients with an average decrease of 16.3 µm compared with HCs. The inner GCIP 
was the parameter with the lowest regression coefficients, ranging from -4.97 µm to -9.81 
µm. This might be due to the combined measurement with the inner plexiform layer masking 
the true reduction of ganglion cells. Previous publications have also reported the T-pRNFL to 
be more reduced than the other quadrants in MS patients (52, 80). The thickness reduction of 
T-pRNFL reported with OCT is supported by the post mortem findings by Evangelou et al. 
(114). They reported that the axons from parvocellular neurons, which are the predominant 
axons of the papillomacular bundle (temporal portion of the pRNFL), showed the largest 
reduction in MS eyes. It is unknown why a preferential damage of axons is found in the 
temporal quadrant. These axons of the parvocellular pathway might be more vulnerable to 
MS damage (52). Another theory is that MS lesions in the visual cortex might cause thinning 
of the T-pRNFL since the central visual field is highly subserved by the visual cortex. This 
increases the possibility that MS lesions in the posterior visual pathway will damage the 
axons supplying the central visual field, i.e. the T-pRNFL (87). PPMS patients do not suffer 
from relapses and therefore have no ON history. Based on our results, we conclude that 
another process, such as retrograde trans-synaptic degeneration or primary retinal pathology, 
might be responsible for the retinal atrophy seen in these patients.  
Ten years ago, Toledo et al. investigated the relationship between pRNFL and physical 
disability and cognitive impairment in MS (115). Both average pRNFL and T-pRNFL were 
associated with EDSS. However, the study was performed by the time of the older generation 
of OCT. Paper II has also shown associations between pRNFL and clinical measures. 
Physical disability, measured with EDSS, was in paper II inversely correlated with average 
pRNFL, inferior pRNFL and T-pRNFL. The highest regression coefficients and p-values 
were found between T-pRNFL, inferior pRNFL and EDSS. Since the T-pRNFL suffers a 
larger proportional loss of axons than the inferior quadrant, changes in T-pRNFL might be 
easier to detect in a clinical setting. Regarding the EDSS scores in paper III, the inner GCC 
and T-pRNFL had the highest regression coefficients and equally strong p-values. Other SD-
OCT studies in the MS field have also reported associations between different OCT measures 
and EDSS. Albrecht et al. found that average pRNFL and total macular thickness correlated 
with EDSS (84). Garcia-Martin et al. reported inverse correlations between thinning of 
pRNFL and GCIP thicknesses and EDSS scores. Also, the GCIP thickness could predict 
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axonal loss in MS patients (116). Same author reported a correlation between pRNFL 
thinning in the superior quadrant and T-pRNFL and EDSS increase over 5 years in RRMS 
patients (117). Another study that only included RRMS patients with EDSS ≤ 3; ≥ 15 years 
could not find a correlation between pRNFL thickness and EDSS. However, this might be 
due to the limited range of EDSS scores (118). The inner GCC is a macular measurement and 
based on our results, it might be an alternative to use this parameter instead of T-pRNFL in 
those patients who have difficulties to fixate during optic disc measurements. 
The relationship between cognitive impairment and OCT parameters have so far only been 
sparsely investigated. Cognitive impairment, measured with SDMT, was mostly associated 
with the inferior quadrant and T-pRNFL in paper II and with T-pRNFL in paper III. Toledo 
et al. evaluated different TD-OCT measures and they observed that the average pRNFL, and 
especially the T-pRNFL, were correlated with several cognitive measures. The strongest 
correlation was found between T-pRNFL and SDMT (115). A cross-sectional study by Coric 
et al., analyzed average pRNFL and macular GCIP in MS patients. They reported a 
significant association between these OCT measures and cognitive impairment (119).  
Garcia-Martin et al. reported that T-pRNFL thinning was associated with reduced quality of 
life. In both paper II and paper III no correlation was found between MSIS-29 and any of the 
investigated OCT parameters (117). Important differences compared to our study was that 
they only included patients with RRMS and used another patient reported outcome. 
The purpose with the longitudinal analysis in paper III was to investigate if the baseline OCT 
measure could predict future worsening in physical disability and/or cognitive impairment in 
MS. However, we did not observe any obvious differences in the rate of change for patients 
with reduced or normal baseline OCT measures. The results might have been different with a 
shorter disease duration since the GCIP thinning has been shown to be more rapid in MS 
patients with a disease duration of less than 5 years (89). SDMT increased significantly by 
1.2 scores on 6-month average over the follow-up time. This is explained by the learning 
effect which is a limitation with SDMT. The idea of using OCT as a predictor of future 
disability in MS has been evaluated in a few studies. Martinez-Lapiscina et al. demonstrated 
that patients with a pRNFL thickness equal to or below 87-88 µm had double the risk of 
disability worsening, measured with EDSS at any point after 1-3 years (33). Coric et al. 
reported increased odds of cognitive impairment in patients without ON history and reduced 
average pRNFL and GCIP thickness (119). 
One strength with paper I was that we analyzed both macular and optic disc parameters in 
both instruments whereas many other studies have only focused on pRNFL or macular 
thickness. One limitation with paper I was that we did not investigate the inter-observer 
variability of Canon-OCT HS100. Strengths with paper II and paper III are the large sample 
size from one single neurology clinic, all MS subtypes were included, and we found OCT 
parameters that correlate with both physical disability and cognitive impairment in MS. One 
limitation with paper II is the cross-sectional design. In paper III we did not have the same 
number of patients through the whole 36-month period and this might influence the results. 
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Limitations in both paper II and paper III is the lack of CIS patients, the small number of 
PPMS patients and that the assessment of previous ON was only based on clinically 
confirmed episodes and patient self-reports.  
6.1 CLINICAL RELEVANCE 
Based on our results and similar previous studies, OCT might be a valuable and 
complementary imaging tool for MS patients. It is a reliable, fast and non-invasive technique, 
providing objective data on axonal and neuronal loss, showing that the retina is a mirror of 
the brain. With the automatic segmentation algorithms, the OCT operator is given a lot of 
information about the different retinal layers. More studies are needed over time to know 
which parameters are the most relevant for clinical practice and trials. However, based on our 
findings in combination with other published data, pRNFL and macular measurements, such 
as inner GCC, would be satisfying when studying neurodegeneration in MS patients. The T-
pRNFL might be the best pRNFL parameter of choice when studying axonal loss related to 
MS. Since many studies, including Paper II and III, have demonstrated the T-pRNFL to be 
remarkably reduced compared to HCs. This is an important finding when differentiating 
between MS and other neurological diseases. Before the time of segmentation algorithms, 
total macular volume was the OCT parameter used for analysis of ganglion cells. Inner GCC 
and inner GCIP are more specific measurements than macular volume and therefore better to 
use when quantifying neuronal loss in MS. 
Although the largest reduction of T-pRNFL was found in PPMS eyes, this group was the 
most difficult to include in our studies. Many of the PPMS patients coming to the clinic 
experienced great difficulties with muscle weakness and/or paralysis. This made it very 
difficult for them to participate in the OCT exam and therefore they could not be included. As 
already mentioned, OCT has many practical advantages, however it should be noted that it 
has limitations when examining MS patients with high EDSS scores. 
6.2 FUTURE PERSPECTIVES 
This thesis focused on investigating the role of OCT as a structural measurement in MS 
patients. Brain volume loss, measured with MRI, is a common measure when studying 
neurodegeneration in MS. Recent studies have suggested OCT as a complement to MRI 
when assessing neurodegeneration. The anterior visual pathway is an easy accessible part of 
the CNS to study the pathophysiology of MS. The ganglion cell layer is the neuronal part, i.e. 
brain gray matter and the RNFL consists of ganglion cell axons, i.e. brain white matter. To 
increase our knowledge about the potentials of OCT in MS it would not only be valuable to 
correlate it with MRI estimates and functional tests, but also to add OCT as an outcome 
measure for measuring treatment response in MS. Regarding functional tests, we only 
included EDSS and SDMT, which are normally a part of the routine examination of MS 
patients. Visual function tests, such as low contrast visual acuity, visual field and/or color 
vision should be added in future studies. 
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This thesis contributes with information about the use of OCT in MS and suggests OCT 
parameters to be associated with both physical disability and cognitive impairment. This 
thesis also confirms earlier cross-sectional studies that pRNFL thickness is significantly 
reduced in MS. The exploratory analysis of longitudinal data over a 36-month period could 
not predict future disability. Such longitudinal studies should focus on CIS or MS with a 
short disease duration. Following these patients over time is necessary to confirm if OCT 
might predict future disability worsening. RNFL and GCIP thickness have been the main 
focus in most published studies. Thickness measurements of deeper retinal layers have been 
performed sparsely in MS patients compared to HCs. The results have varied and therefore 
further studies are needed. A large post mortem study by Green et al. gives evidence for 
atrophy of the INL (82). The INL thickness and the use of OCT angiography will be of 
particular interest in MS studies focusing on inflammation. 
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7 CONCLUSIONS 
• Canon OCT-HS100 reported thicker values for almost all investigated parameters 
compared with Zeiss Cirrus HD-OCT 5000. The difference was significant in the 
macular region with an average of 24 µm thicker values with Canon OCT-HS100. It 
is most likely due to different reference planes and this finding makes it clear that 
OCTs are not interchangeable. 
• The pRNFL thickness in the unaffected fellow eye of MSON+ showed a similar 
reduction (-4.5 µm thinner than HCs) as the MS eyes without previous ON in any eye 
(-6 µm thinner than HCs). 
• Axonal loss, measured as pRNFL thickness with OCT, could be demonstrated in all 
MS subtypes compared with HCs. The T-pRNFL of PPMS patients was the most 
reduced pRNFL quadrant compared with HCs with a mean reduction of 15.8 µm, 
ranging from -21.4 µm to -10.1 µm. Our results suggest that the T-pRNFL thickness 
might be an important measurement to differentiate MS subtypes. 
• Retinal thickness reduction, measured with OCT, is associated with physical 
disability, assessed with EDSS, and with cognitive impairment, assessed with SDMT. 
T-pRNFL is the quadrant with the strongest association with both EDSS and SDMT 
according to the regression coefficients and p-values. Inner GCC was the macular 
OCT parameter with the highest association to these functional tests and might be a 
good option in patients with difficulties to participate in optic disc measurements. 
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